Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)

被引：0
|
作者：
Ramalingam, S. S.
Maitland, M.
Frankel, P.
Argiris, A. E.
Koczywas, M.
Gitlitz, B.
Espinoza-Delgado, I.
Vokes, E. E.
Gandara, D. R.
Belani, C. P.
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ So Calif, Los Angeles, CA USA
[6] NCI, Bethesda, MD 20892 USA
[7] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
[8] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8004
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer
    Chen, Zhiwei
    Chen, Jianhua
    Huang, Dingzhi
    Zhang, Wei
    Wu, Lin
    Yi, Tienan
    Wang, Qiming
    Han, Liang
    Tan, Liping
    Li, Yinyin
    Zhang, Zhihong
    Li, Na
    Li, Jie
    Zhang, Tongmei
    Hu, Ying
    Sun, Hongmei
    Wu, Youhua
    He, Zhiyong
    Yang, Runxiang
    Cheng, Peng
    Li, Xingya
    Shi, Jianhua
    Yu, Guohua
    Ma, Daiyuan
    Li, Benjamin Xiaoyi
    Dai, Xiangrong
    Wong, Michael
    Li, Yujie
    Yu, Xiaohui
    Lu, Shun
    Socazolimab Study Grp, Benjamin Xiaoyi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [22] Randomized, double-blind, placebo-controlled, phase III multicentre study of paclitaxel plus carboplatin (TC) versus TC plus endostar in patients with advanced non-small cell lung cancer (NSCLC)
    Han Baohui
    Xiu Qingyu
    Wang Huiming
    Luo Yi
    Bai Chunxue
    Guo Shuliang
    Liu Wenchao
    Zhuang Zhixiang
    Zhang Yang
    Zhou Jianying
    Jing Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S354
  • [23] A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Paz-Ares, Luis
    Balint, Beatrix
    de Boer, Richard H.
    van Meerbeeck, Jan P.
    Wierzbicki, Rafal
    De Souza, Paul
    Galimi, Francesco
    Haddad, Vincent
    Sabin, Tony
    Hei, Yong-jiang
    Pan, Yang
    Cottrell, Susan
    Hsu, Cheng-Pang
    RamLau, Rodryg
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 329 - 337
  • [24] Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer.
    Rose, V
    Schiller, J
    Wood, A
    Eskander, E
    Holroyd, K
    Desai, A
    Lee, JT
    Ahmed, M
    Kim, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [25] A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
    Zhao, Hongyun
    Zhang, Zhonghan
    Luo, Fan
    Ma, Yuxiang
    Fang, Wenfeng
    Yang, Yunpeng
    Zhang, Yang
    Huang, Yan
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Rh-endostatin Injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: Randomized, double-blind, placebo-controlled, multicentre study
    Han, B.
    Xiu, Q.
    Wang, H.
    Luo, Y.
    Zhuang, Z.
    Jin, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer
    Jahnke, Kristoph
    Keilholz, Ulrich
    Lueftner, Diana
    Thiel, Eckhard
    Schmittel, Alexander
    ANTICANCER RESEARCH, 2011, 31 (01) : 317 - 323
  • [28] Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
    Heymach, John V.
    Paz-Ares, Luis
    De Braud, Filippo
    Sebastian, Martin
    Stewart, David J.
    Eberhardt, Wilfried E. E.
    Ranade, Anantbhushan A.
    Cohen, Graham
    Trigo, Jose Manuel
    Sandler, Alan B.
    Bonomi, Philip D.
    Herbst, Roy S.
    Krebs, Annetta D.
    Vasselli, James
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5407 - 5415
  • [29] ANALYSIS OF CROSS-OVER PORTION OF ENCORE-401, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF ERLOTINIB WITH AND WITHOUT ENTINOSTAT, A CLASS 1 ISOFORM SELECTIVE HISTONE DEACETYLASE INHIBITOR (HDAC) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Witta, Samir
    Jotte, Robert
    Neubauer, Marcus
    Spire, Alexander
    Ruxer, Robert
    Konduri, Kartik
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1314 - S1314
  • [30] DAILY ORAL PERIFOSINE IN COMBINATION WITH RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: FIRST RESULTS OF A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE II STUDY
    Verheij, M.
    Karchmit, Y.
    Bakardjiev, S.
    Beliaukouski, V.
    Savu, M.
    Smickoska, S.
    Sindermann, H.
    Markivskyy, A.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S167 - S167
12345